Literature DB >> 20164540

Analysis of the expression of human tumor antigens in ovarian cancer tissues.

Rouba Ali-Fehmi1, Madhumita Chatterjee, Alexei Ionan, Nancy K Levin, Haitham Arabi, Sudeshna Bandyopadhyay, Jay P Shah, Christopher S Bryant, Stephen M Hewitt, Michael G O'Rand, Oleg M Alekseev, Robert Morris, Adnan Munkarah, Judith Abrams, Michael A Tainsky.   

Abstract

Biomarkers for early detection of cancer have great clinical diagnostic potential. Numerous reports have documented the generation of humoral immune responses that are triggered in response to changes in protein expression patterns in tumor tissues and these biomarkers are referred to as tumor associated antigens (TAAs). Using a high-throughput technology, we previously identified 65 proteins as diagnostically useful TAAs by profiling the humoral immune responses in ovarian cancer (OVCA) patients. Here we determined the expression status of some of those TAAs in tissues from OVCA patients. The protein expression patterns of 4 of those 65 antigens, namely NASP, RCAS1, Nijmegen breakage syndrome1 (NBS1) and eIF5A, along with p53 and Her2 (known molecular prognosticators) and two proteins that interact with NBS1, MRE11 and RAD50, were assessed by immunohistochemistry (IHC). NASP and RCAS1 proteins were more frequently expressed in ovarian cancer tissues than with normal ovarian tissue and serous cystadenomas and MRE11 was less frequently expressed. When evaluated simultaneously, only NASP and MRE11 remained statistically significant with sensitivity of 66% and specificity of 89%. None of these proteins' expression levels were prognostic for survival. Together, our results indicate that occurrence of humoral immune responses against some of these TAAs in OVCA patients is triggered by antigen protein overexpression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20164540      PMCID: PMC3343030          DOI: 10.3233/CBM-2009-0117

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  48 in total

Review 1.  T cell anergy and costimulation.

Authors:  Leonard J Appleman; Vassiliki A Boussiotis
Journal:  Immunol Rev       Date:  2003-04       Impact factor: 12.988

2.  A serologically identified tumor antigen encoded by a homeobox gene promotes growth of ovarian epithelial cells.

Authors:  H Naora; Y Q Yang; F J Montz; J D Seidman; R J Kurman; R B Roden
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

3.  Identification of tumor-restricted antigens NY-BR-1, SCP-1, and a new cancer/testis-like antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum.

Authors:  Dirk Jäger; Marc Unkelbach; Claudia Frei; Florian Bert; Matthew J Scanlan; Elke Jäger; Lloyd J Old; Yao-Tseng Chen; Alexander Knuth
Journal:  Cancer Immun       Date:  2002-06-28

4.  Overexpression of the Linker histone-binding protein tNASP affects progression through the cell cycle.

Authors:  Oleg M Alekseev; David C Bencic; Richard T Richardson; Esther E Widgren; Michael G O'Rand
Journal:  J Biol Chem       Date:  2002-12-30       Impact factor: 5.157

Review 5.  Glycosylation defining cancer malignancy: new wine in an old bottle.

Authors:  Senitiroh Hakomori
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-30       Impact factor: 11.205

6.  Nijmegen breakage syndrome gene (NBS1) alterations and its protein (nibrin) expression in human ovarian tumours.

Authors:  J Plisiecka-Hałasa; A Dansonka-Mieszkowska; A Rembiszewska; M Bidziński; J Steffen; J Kupryjańczyk
Journal:  Ann Hum Genet       Date:  2002-11       Impact factor: 1.670

7.  Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer.

Authors:  M L Disis; K L Knutson; K Schiffman; K Rinn; D G McNeel
Journal:  Breast Cancer Res Treat       Date:  2000-08       Impact factor: 4.872

8.  Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.

Authors:  Marcia S Brose; Timothy R Rebbeck; Kathleen A Calzone; Jill E Stopfer; Katherine L Nathanson; Barbara L Weber
Journal:  J Natl Cancer Inst       Date:  2002-09-18       Impact factor: 13.506

9.  Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression.

Authors:  M J Scanlan; I Gout; C M Gordon; B Williamson; E Stockert; A O Gure; D Jäger; Y T Chen; A Mackay; M J O'Hare; L J Old
Journal:  Cancer Immun       Date:  2001-03-30

Review 10.  Serum HER-2/neu in the management of breast cancer patients.

Authors:  Diana Lüftner; Claudia Lüke; Kurt Possinger
Journal:  Clin Biochem       Date:  2003-06       Impact factor: 3.281

View more
  9 in total

1.  BRCA1-mediated signaling pathways in ovarian carcinogenesis.

Authors:  Tejaswita M Karve; Xin Li; Tapas Saha
Journal:  Funct Integr Genomics       Date:  2011-09-02       Impact factor: 3.410

2.  Unraveling molecular effects of ADAR1 overexpression in HEK293T cells by label-free quantitative proteomics.

Authors:  Jisheng Guo; Xiaoyue Wang; Xin Lü; Ruirui Jing; Junqiang Li; CuiLing Li; Daoguang Wang; Baibin Bi; Xinjun Chen; Fengqin Wang; Shengnan Sun; Jing Gong; Kazem M Azadzoi; Jing-Hua Yang
Journal:  Cell Cycle       Date:  2016-04-22       Impact factor: 4.534

3.  Initiation and elongation factor co-expression correlates with recurrence and survival in epithelial ovarian cancer.

Authors:  Monika Sobočan; Daniela Brunialti; Sussanne Sprung; Christoph Schatz; Jure Knez; Rajko Kavalar; Iztok Takač; Johannes Haybaeck
Journal:  J Ovarian Res       Date:  2022-06-19       Impact factor: 5.506

4.  Serum prognostic biomarkers in head and neck cancer patients.

Authors:  Ho-Sheng Lin; Fauzia Siddiq; Harvinder S Talwar; Wei Chen; Calin Voichita; Sorin Draghici; Gerald Jeyapalan; Madhumita Chatterjee; Andrew Fribley; George H Yoo; Seema Sethi; Harold Kim; Ammar Sukari; Adam J Folbe; Michael A Tainsky
Journal:  Laryngoscope       Date:  2014-01-29       Impact factor: 3.325

5.  The analysis of receptor-binding cancer antigen expressed on SiSo cells (RCAS1) immunoreactivity within the microenvironment of the ovarian cancer lesion relative to the applied therapeutic strategy.

Authors:  Wojciech Jozwicki; Wieslawa Windorbska; Anna A Brozyna; Cezary Jochymski; Pawel Basta; Jerzy Sikora; Elzbieta Stasienko; Magdalena Dutsch-Wicherek; Krzysztof Koper; Lukasz Wicherek
Journal:  Cell Tissue Res       Date:  2011-08-16       Impact factor: 5.249

6.  Molecular evolution of NASP and conserved histone H3/H4 transport pathway.

Authors:  Syed Nabeel-Shah; Kanwal Ashraf; Ronald E Pearlman; Jeffrey Fillingham
Journal:  BMC Evol Biol       Date:  2014-06-20       Impact factor: 3.260

7.  Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.

Authors:  Simone Brandt; Eleftherios P Samartzis; Anne-Katrin Zimmermann; Daniel Fink; Holger Moch; Aurelia Noske; Konstantin J Dedes
Journal:  BMC Cancer       Date:  2017-01-10       Impact factor: 4.430

8.  Knockdown of long noncoding RNA colorectal neoplasia differentially expressed inhibits hepatocellular carcinoma progression by mediating the expression of nuclear autoantigenic sperm protein.

Authors:  Yungang Zhu; Baoguo Li; Guoping Xu; Changrui Han; Gang Xing
Journal:  Oncol Rep       Date:  2021-10-11       Impact factor: 3.906

9.  Expression of Tra2 β in Cancer Cells as a Potential Contributory Factor to Neoplasia and Metastasis.

Authors:  Andrew Best; Caroline Dagliesh; Ingrid Ehrmann; Mahsa Kheirollahi-Kouhestani; Alison Tyson-Capper; David J Elliott
Journal:  Int J Cell Biol       Date:  2013-07-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.